Angelo Moore looks into the camera in front of a plain background

WATCH: OHE Hosts "Barbershop Talk" on Prostate Cancer






This event has passed.

Office of Health Equity Virtual Series: Conversations with Our Community

Black/African American men are twice as likely as white men to die of prostate  cancer and continue to have the highest prostate cancer death rate among all U.S. population groups.

On September 14, the DCI Office of Health Equity (OHE) hosted "Barbershop Talk—  Let's Have a Man to Man Discussion About Prostate Cancer" — as part of it's signature Conversations with Our Community series.

The public discussion featured DCI urologic surgical oncologist Cary Robertson, MD, and was moderated by OHE program leader Angelo Moore, PhD, RN, NE-BC.

Panelists included Demetrius Harvey (a member of the DCI Community Advisory Council, assistant director, Black Men's Health Initiative, and a member of the Kappa Alpha Psi Fraternity), Earle Manhertz (a member of the Men's Health Council of Durham County) and Jeff Dowd (member of DCI Community Advisory Council). The speakers discussed the importance of prostate cancer screening, diagnosis, treatment and participation in clinical trials from the perspective of urologic oncologists, prostate cancer survivors, and caregivers. 

Learn More About the Oncologist

In addition to being a practicing urologic surgical oncologist, Cary Robertson, MD, is an associate professor in the Duke Department of Surgery, Duke University School of Medicine.

His areas of expertise include:

  • High Intensity Focused Ultrasound Therapy of Prostate Cancer
  • Surgical Technique Improvement in Prostate Cancer
  • Clinical Predictors of Outcome in Prostate Cancer
  • Molecular Imaging and Genomics of Genitourinary Malignancies
  • Quality of Life measures in Genitourinary Malignancies

Robertson is currently the principal investigator on a seven-year (2020-2027) phase 3 "Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy," which was awarded by Janssen Research & Development, LLC.